3.66

1.95% +0.0700

(After Hours: 3.66 0 +0.00%)

News Options Financials Holders Transactions Discussions Predictions

Apr-20-21 08:00AM	Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory BoardGlobeNewswire
Apr-19-21 09:16AM	Ovid Therapeutics Stops Gaboxadol Development Citing Limited Efficacy In Rare Neurological ConditionsBenzinga
08:00AM	OVID Provides Update on OV101 Program and the Prioritization of its ResourcesGlobeNewswire
Mar-30-21 08:00AM	Ovid Therapeutics Announces Closing of Agreement with Takeda for Global Development and Commercialization of SoticlestatGlobeNewswire
Mar-20-21 04:51AM	News Flash: Analysts Just Made A Notable Upgrade To Their Ovid Therapeutics Inc. (NASDAQ:OVID) ForecastsSimply Wall St.
Mar-16-21 08:39AM	Ovid Posts Larger-Than-Feared Quarterly Loss, Revenue BeatSmarterAnalyst
Mar-15-21 08:00AM	Ovid Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update for 2021GlobeNewswire
Mar-10-21 03:44AM	What Kind Of Investors Own Most Of Ovid Therapeutics Inc. (NASDAQ:OVID)?Simply Wall St.
Mar-03-21 07:46AM	The Daily Biotech Pulse: KemPharm ADHD Drug Gets The Nod, MediciNova Shelves Vaccine StudyBenzinga
07:40AM	5 Top Stock Gainers for Wednesday: Michaels, Alcoa, Ovid TherapeuticsTheStreet.com
Mar-03-21 07:00AM	Takeda buys epilepsy treatment rights from Ovid for up to $856 mlnReuters
07:00AM	Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut SyndromeBusiness Wire
Jan-15-21 02:22AM	Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?Simply Wall St.
Dec-16-20 07:00AM	Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology IndexGlobeNewswire
12:30PM	Is OVID A Good Stock To Buy Right Now?Insider Monkey
Dec-02-20 11:38AM	Why Ovid Therapeutics Stock Is Imploding TodayMotley Fool
11:30AM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Ovid Therapeutics Inc. (OVID) InvestigationACCESSWIRE
Dec-02-20 09:52AM	Benzinga's Top Upgrades, Downgrades For December 2, 2020Benzinga
07:35AM	The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA NodBenzinga
Dec-01-20 04:52AM	Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary EndpointGlobeNewswire
Nov-25-20 08:51AM	Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock?Zacks
Nov-23-20 04:01AM	Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual CongressGlobeNewswire
Nov-16-20 06:07AM	These Analysts Think Ovid Therapeutics Inc.'s (NASDAQ:OVID) Sales Are Under ThreatSimply Wall St.
Nov-12-20 04:10AM	Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
Oct-14-20 07:00AM	Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development ProgramGlobeNewswire
Oct-12-20 07:00AM	Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual CongressGlobeNewswire
Oct-05-20 05:30AM	Opthea to Appoint Dr Jeremy Levin as Chairman of the BoardGlobeNewswire
Sep-30-20 08:00AM	Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare EpilepsiesGlobeNewswire
Sep-11-20 08:00AM	Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewswire
Aug-25-20 07:50AM	Ovid Therapeutics Announces Pricing of $50 Million Offering of Common StockGlobeNewswire
07:00AM	Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut SyndromeBusiness Wire
Aug-10-20 08:00AM	Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
Aug-05-20 09:00AM	Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020GlobeNewswire
Jul-25-20 09:10AM	3 Top Biotech Stocks to Buy NowMotley Fool
Jul-23-20 07:00AM	Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman SyndromeGlobeNewswire
Jul-14-20 06:35AM	Is Ovid Therapeutics Stock a Buy?Motley Fool
Jul-13-20 09:00AM	Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in EuropePR Newswire
07:35AM	How Much Of Ovid Therapeutics Inc. (NASDAQ:OVID) Do Insiders Own?Simply Wall St.
Jul-08-20 09:20AM	Is Ovid Therapeutics Inc. (OVID) Going to Burn These Hedge Funds?Insider Monkey
Jun-29-20 08:00AM	Ovid Therapeutics Added to Russell 2000® and Russell 3000® IndexesGlobeNewswire
Jun-25-20 08:58AM	Ovid Therapeutics (OVID) Jumps: Stock Rises 12.4%Zacks
Jun-22-20 09:02AM	Implied Volatility Surging for Ovid Therapeutics (OVID) Stock OptionsZacks
Jun-19-20 08:00AM	Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman SyndromeGlobeNewswire
Jun-11-20 08:00AM	Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological DiseasesGlobeNewswire
Jun-08-20 08:00AM	Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights PlatformGlobeNewswire
Jun-04-20 08:00AM	Ovid Therapeutics Launches Pipeline Teach-In Webinar SeriesGlobeNewswire
May-12-20 08:00AM	Ovid Therapeutics Announces Participation in the 2020 RBC Capital Markets Virtual Global Healthcare ConferenceGlobeNewswire
May-07-20 08:00AM	Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewswire
07:30AM	Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X SyndromeGlobeNewswire
Apr-22-20 11:50AM	Top Ranked Momentum Stocks to Buy for April 22ndZacks

Ovid Therapeutics (OVID) Stock Discussions on Social Media

- OVID Stock on Twitter: https://twitter.com/search?q=$ovid
- OVID Stock on Reddit: https://www.reddit.com/search/?q=$ovid
- OVID Stock on SeekingAlpha: https://seekingalpha.com/symbol/OVID

More Discussions

NSX · April 17, 2021

Sold all today! This #$%$ is going nowhere!

Upvote: 2 · Downvote: 1 · Replies: 0

Ulrich · April 16, 2021

New 13G filing (3rd Amendmend) released yesterday (filed April, 13)Increased ownership.https://www.sec.gov/Archives/edgar/data/918923/000092189521001066/sc13ga307422ovid_04152021.htm

Upvote: 3 · Downvote: 0 · Replies: 0

NSX · April 15, 2021

$4.50 resistance... once it breaks $10+ is possible!

Upvote: 1 · Downvote: 0 · Replies: 0

NSX · April 14, 2021

Sold all my long shares today and went Shorted 😂

Upvote: 1 · Downvote: 2 · Replies: 2

Rodney · April 14, 2021

It's alive!

Upvote: 1 · Downvote: 0 · Replies: 0

NSX · April 10, 2021

$196 million to the pockets of Ovid execs yuck!

Upvote: 3 · Downvote: 0 · Replies: 0

Gordon · April 10, 2021

The big boys buy large amounts of stock in companies that have poor PR skills but are fundamentally a good buy. Lease the shares back to shorters (generating income), price falls, big guys soak up the cheap shares, abracadabra stock becomes unavailable to shorters, SP rises, big boys cash out. $OVID has an MCap pretty much on par with its cash position with future royalties in da bag. Ride the wave.

Upvote: 0 · Downvote: 0 · Replies: 0

NSX · April 07, 2021

They are loosing investors confidence! Boohoo! Is slowly going down to $2

Upvote: 1 · Downvote: 0 · Replies: 0

wscott · April 07, 2021

Thirsty

Upvote: 1 · Downvote: 0 · Replies: 0

Rodney · April 07, 2021

From the most recent earning PR:Ovid CEO Jeremy M. Levin said, “This new agreement with Takeda strategically positions Ovid, upon closing, to advance our next generation neuroscience pipeline, while demonstrating the value we helped to create for soticlestat by bringing it to the initiation of two pivotal Phase 3 trials.”“We are excited for next steps both for this asset and for our pipeline, as we work to file three INDs over the next three years and in tandem pursue an active business development initiative,” Levin added.So, Jeremy, what say you now? Please issue another PR to discuss the next generation neuroscience pipeline and the upcoming three INDs for 'business development initiatives' (whatever that means). Please elaborate. Now would be a good time. Thanks.

Upvote: 3 · Downvote: 0 · Replies: 0

Scott · April 06, 2021

Timing is everything in the markets. If today's news would have been released just a few weeks ago, OVID would have risen at least 40%. Now we are barely treading water on today's fantastic news. Unbelievable. Herd mentality. Where is that robinhood gang when you need them? lol. GLTA.

Upvote: 8 · Downvote: 0 · Replies: 0

ValuFin · April 06, 2021

I’m waiting into Q2, when Takeda initiates the phase 3 trial, and pays OVID yet again another decent milestone amount.

Upvote: 1 · Downvote: 0 · Replies: 0

Gordon · April 06, 2021

Bio market has been poor the last few weeks due to a mixture of reasons. $OVID has been hanging on. Stock will continue to rise albeit maybe not as fast as day traders would like. I'm well up but will continue to hold.

Upvote: 1 · Downvote: 3 · Replies: 0

Ben · April 06, 2021

Deal done - $196 million

Upvote: 7 · Downvote: 0 · Replies: 0

Gordon · April 06, 2021

If it goes to 6.00 then that's approx 370mil MCap. With a bit of basic PR that should be easy based on cash position and potential future milestone revenue not to mention reduction in R&D costs and other product pipeline.

Upvote: 2 · Downvote: 0 · Replies: 0

wscott · April 06, 2021

OK... trading now @ cash...low float, high short content...where are the GME gamers to initiate a slow but solid squeeze?

Upvote: 4 · Downvote: 0 · Replies: 0

Dean · April 06, 2021

Why are we not popping today??? This is crazy. The company gets nearly the same in cash as their entire market cap, and the stock doesn't move???

Upvote: 4 · Downvote: 0 · Replies: 0

Philippe · April 06, 2021

196 million in cash for a 250 million market cap.. How is this not moving

Upvote: 1 · Downvote: 1 · Replies: 2

Evan · April 06, 2021

I don’t know what got into me yesterday, but I got discouraged when nothing happened after the catalyst and got out. Now I’m watching from the sidelines. Why do I sabotage myself?

Upvote: 7 · Downvote: 0 · Replies: 0

Bruno · April 06, 2021

There are 196 million reasons for the stock price to increase $1 a share.

Upvote: 6 · Downvote: 0 · Replies: 0

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate that is in Phase Ib/IIa trial for rare epileptic encephalopathies; preclinical-stage compounds for rare epilepsy disorders; and OV102, an intravenous formulation for indications in the clinical setting. The company has collaboration agreement with Takeda Pharmaceutical Company Limited. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.

List of Zack Morris Stocks List of SPAC Stocks List of EV Stocks and Related Stocks Top 100 popular stocks on Robinhood List of Marijuana Stocks

Open in Yahoo | Open in Google | Open in Finviz